Citius Oncology reports positive Phase 1 data for LYMPHIR-Pembrolizumab combo
Share
Citius Oncology (NASDAQ:CTOR) reported positive topline results on Tuesday from an investigator-initiated Phase 1 clinical trial evaluating its flagship immunotherapy, LYMPHIR (denileukin diftitox-cxdl), in combination with Merck’s pembrolizumab (Keytruda).
